Urinary clusterin as a biomarker of human kidney disease progression and response to the endothelin receptor antagonist atrasentan: An exploratory analysis from the SONAR trial
- Wenjun Ju
- Viji Nair
- Priya Vart
- J. David Smeijer
- Kelly L. Hudkins
- Erik Moedt
- Maria Larkina
- Paul Perco
- Frederic Burdet
- Kerby Shedden
- Michael Hwang
- Edmond Lee
- Christopher O’Connor
- John Hartman
- Lalita Subramanian
- Markus Bitzer
- Mark Ibberson
- Kevin L. Duffin
- Maria F. Gomez
- Charles E. Alpers
- Matthias Kretzler
- Hiddo J. L. Heerspink
2026-02-07